Contact

Directions

About Us

Technology Offers

Animal Models
Ascenion

Animal Models
MGC Foundation

	A Central Target in Neutrophil Granulopoiesis
	A method for inducing cellular apoptosis
	Acute Liver Failure
	Aß-directed Peptides
	New Ansamitocin analogues for the treatment of cancer
	Argyrin – A promising novel anti-cancer compound
	Broad-spectrum antiviral peptides
	Metabolic Syndrome
	Biocompatible matrix
	CD 3 Kappa Immune enhancing drug
	CD 3 Kappa adjuvant
	CFHR proteins – Novel regulators of the innate immune system
	DC Maturation Cocktail
	TH-1 Stimulation
	direct epitope/antigen identification
	EBV-VLP as vaccine
	Expression of immunoglobulin-cytokine fusion proteins
	GARP controlling Treg
	Hepatocytes
	Her2/neu-specific T cell receptors
	IL-6 /IL-8 Inhibitor
	Regenerationskinase
	Hair Loss
	Immunomodulating Peptide
	Induced senescence against tumor genesis
	Lipoxygenase wound healing
	Macrophage Stimulation
	MHC Loading Catalysis
	MicroRNA-221 – new treatment option for fulminant liver failure
	Myosin-Inhibitors
	NEP & eating disorders
	Nerve guidance conduit
	New Antidepressant Target
	Anti-cancer Drugs
	Novel Antimicrobial Peptides
	Novel Antimicrobial and Antiviral Peptides
	T cell population in HIV
	Obesity-associated Diabetis
	Pain Therapy Identification
	Peptide for improved pain management
	Primary Haemostasis
	Sepsis Therapy via NK cells
	Sepsis Treatment
	Stabilized Etnangien derivative – antibiotic drug candidate from myxobacteria
	TAK1 - regenerative therapy
	TCR gene transfer for CLL
	Treatment of anxiety and depression
	Technology Offer
	Treatment of EBV-associated diseases
	Treatment of sepsis with MALP-2
	Tumor Targeting

Tools

Vaccines

Veterinary Medicine

Immunomodulating Protein from Schistosoma mansoni for the Treatment of Autoimmune Diseases

Reference Number TO 14-00008

The Challenge
A pathological immune response is the major cause for a number of disease states including autoimmune diseases, acute transplant rejection or allergic reactions. Hence modulation of the immune response, e.g. the redirection of a Th1 response towards a Th2 response, has gained wide acceptance as a promising therapeutic option. New potent substances are needed, that specifically modulate the immune response without causing side-effects.

Immunomodulating properties of IPSE/alpha-1. A) IPSE/alpha-1 protein (red) is localized directly underneath the egg shell in S. mansoni eggs and (following secretion) modulates the host immune response. B) Both natural (nIPSE) and recombinant (produced in E. coli, HEK or insect cell lines) IPSE/alpha-1 proteins are potent inducers of IL-4 in basophils.

The Technology
The eggs of the parasitic trematode Schistosoma mansoni induce a pronounced Th2 response and immunoglobulin E (IgE) production both in humans and in experimental animals. In egg extracts the protein IPSE/alpha-1 has been identified as a molecule with highly potent immunomodulating properties. Cell culture experiments show that even very low concentrations of IPSE/alpha-1 lead to the release of IL-4 and IL-13 from basophilic granulocytes.

Commercial Opportunity
The proven immunomodulating properties of IPSE/alpha-1 make this protein an interesting candidate for developing a therapeutic agent. The technology is offered for licensing or for further development in a cooperation.

Patent Situation
Pending patent applications in Germany (DE10109844A1), Europe (EP1363937A2), USA (US20040253709A1) and Japan (JP2004535172T2) claiming priority in March 2001.

Further Reading
G. Schramm et al. Journal of Biological Chemistry (2003), 278: 18384-92
G. Schramm et al. Molecular and Biochemical Parasitoloy (2006), 147: 9-19
G. Schramm et al. Journal of Immunology, in press

Download PDF

Contact:

Dr. Hinrich Habeck
Technology Scout
T + 49 (0) 40 226 11 278
F + 49 (0) 40 226 11 275
habeck@ascenion.de

Imprint

Sitemap